Navigation Links
NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
Date:3/19/2009

nic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the Company believes offers significant advantages over other pain therapies. NeurogesX submitted a new drug application (NDA) for Qutenza to the U.S. Food and Drug Administration (FDA) in October 2008 for PHN, which was accepted for filing by the FDA in December 2008. A marketing authorization application (MAA) for Qutenza received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending approval for peripheral neuropathic pain in non-diabetic adults alone or in combination with other medicinal products for pain. NeurogesX is currently awaiting the European Commission's decision on the CHMP's opinion.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently evaluating the timing of entering Phase 2 development.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor f
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
2. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
3. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
4. NeurogesX Reports Third Quarter 2008 Results
5. NeurogesX to Report Third Quarter 2008 Financial Results
6. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
7. NeurogesX Responds to EMEAs Day 120 Questions
8. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
9. NeurogesX Reports Second Quarter 2008 Results
10. NeurogesX to Report Second Quarter 2008 Financial Results
11. NeurogesX Opens Investigational New Drug Application for Capsaicin Liquid Formulation NGX-1998
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... DUBLIN, Ireland , September 18, ... ,Research and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) ... "Biocompatible Materials - Global Strategic ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report ... Materials in US$ Million by the ...
(Date:9/18/2014)... Washington, D.C. (PRWEB) September 18, 2014 ... Dick Durbin and Sen. Jim Risch for National Lab ... research projects from across the national laboratory system. Durbin ... Caucus, which aims to increase awareness of the reach ... breakthrough technologies and discoveries to address some of our ...
(Date:9/18/2014)... Research and Markets has ... Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on ... The report provides a basic overview ... industry chain structure. The N-acetylcysteine market analysis is ...
(Date:9/18/2014)... 2014 Research and Markets has ... (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends ... The global companion diagnostics market is ... 2014 to 2019. Factors such as rising need for ... diagnostics by the pharmaceutical industry, support from regulatory authorities, ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Global N-acetylcysteine Industry Report 2014 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3
... CRANBURY, N.J., Sept. 12 Amicus Therapeutics,(Nasdaq: FOLD ... Officer, will present a corporate update at the Merrill ... United,Kingdom on Tuesday, September 18th at 4:00 pm BDT ... A live audio web cast of the presentation will ...
... MORRISVILLE, N.C., Sept. 12 AVOS Life Sciences,announced ... Vice President. His,primary responsibility will be providing advisory ... areas as well as selected investment,assignments in capital ... he will also have responsibility for AVOS, emerging ...
... Robotic-Assisted Coronary ... Artery Bypass Surgery, REDWOOD CITY, Calif., ... it has received European CE Mark,(Conformite Europeenne) approval for the C-Port(R) ... of Cardica,s C-Port(R) xA,Distal Anastomosis System product line and further facilitates ...
Cached Biology Technology:Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference 2Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference 3Senior Research Analyst Richard Evans Joins AVOS Life Sciences 2Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery 2Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery 3
(Date:9/18/2014)... Americans across racial and ethnic groups describe losing ... their day-to-day life, more so than other conditions ... (57% of African-Americans, 49% of non-Hispanic whites, 43% ... which disease or ailment is the worst that ... African-Americans followed by AIDS/HIV. Hispanics and Asians ...
(Date:9/18/2014)... algal forests in the eastern Mediterranean Sea pose a ... distribution continues to expand as the climate warms, a ... of researchers led by Dr Adriana Vergs of UNSW ... for Advanced Studies in Spain, is published in the ... surveyed more than 1000 kilometres of coastline in Turkey ...
(Date:9/18/2014)... too stressed they are often grouchy, grumpy, nasty, distracted ... at EPFL have just highlighted a fundamental synaptic mechanism ... loss of social skills and cognitive impairment. When triggered ... in the brain. This was revealed by a work ... Sandi,s team went to look for answers in a ...
Breaking Biology News(10 mins):Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3Tropical fish a threat to Mediterranean Sea ecosystems 2How stress tears us apart 2
... last couple decades have seen a virtual renaissance of ... functional magnetic resonance imaging (fMRI). Thanks to a ... scholars at Rutgers University will have the latest fMRI ... NSF has awarded Rutgers University in Newark a $1,820,000 ...
... natural organic pesticide for hundreds of years, is getting new ... pesticides. That,s the topic of a report in ACS, bi-weekly ... Cedric Briens and colleagues note that concerns about the health ... in some parts of the world. Scientists are looking for ...
... geoscientist Dr Veerle Huvenne of the United Kingdom,s National Oceanography ... 1.4 million Euros over five years to map complex habitats ... The European Research Council (ERC) ,Starting Grant, scheme aims ... their own research groups. The grants are highly competitive, and ...
Cached Biology News:$1,820,000 from NSF awarded to Rutgers-Newark to acquire fMRI dedicated to research 2
... Ascent is the first nephelometer ... microplates. Nepheloskan measures light scattering ... for particle quantification. This makes ... in drug discovery, immunoprecipitation, and ...
Anti-VDAC (Voltage-Dependent Anion Channel) AVOID FREEZE/THAW CYCLES. Recognizes the porin 31HL protein. Corresponds to mAb 1 in the literature....
6 x Blend of rTth DNA Polymerase and Tli to provide optimized amounts of both 5-3 and 3-5 proofreading activity...
... Rotarods are used to assess the effect of ... on mice and rats using one unit in ... the animals are placed on textured drums to ... individual sensing platforms below, its test results are ...
Biology Products: